XML 41 R26.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and License Agreements and Supply Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Collaboration And License Agreements And Supply Agreements [Abstract] |
Summary of Recognized Revenue | In accordance with the collaboration agreements, the Company recognized revenue as follows:
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
|  | (in thousands) |  |  | (in thousands) |
Bristol Myers Squibb Company ("BMS") (1) |  | $ | 7,119 |  |  | $ | 3,354 |  |  | $ | 10,673 |  |  | $ | 6,599 |
Merck Sharp & Dohme Corporation (“Merck”) (2) |  |  | 9,055 |  |  |  | 5,488 |  |  |  | 18,837 |  |  |  | 15,620 |
Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name “EMD Serono”) |  |  | 1,507 |  |  |  | 2,649 |  |  |  | 4,656 |  |  |  | 8,145 |
Vaxcyte (3) |  |  | 142 |  |  |  | 786 |  |  |  | 278 |  |  |  | 1,067 |
Total revenue |  | $ | 17,823 |  |  | $ | 12,277 |  |  | $ | 34,444 |  |  | $ | 31,431 |
| (1) | In January 2019, BMS announced the entry into a definitive agreement to acquire Celgene and the transaction was completed in November 2019.
| (2) | Merck was a related party until the closing of the Company’s public offering on May 14, 2020.
| (3) | Vaxcyte was a related party until the closing of its initial public offering on June 16, 2020.
Summary of Deferred Revenue Balance | The following table presents the changes in the Company’s deferred revenue balance from collaboration agreements during the nine months ended September 30, 2020:
|  | Nine Months Ended |
|  | September 30, 2020 |
|  | (in thousands) |
Deferred revenue—December 31, 2019 |  | $ | 35,660 |
Additions to deferred revenue |  |  | 7,543 |
Recognition of revenue in current period |  |  | (19,134 | )
Deferred revenue—September 30, 2020 |  | $ | 24,069 |

X
- Definition Collaboration and license agreements and supply agreements. + References No definition available. + Details
Name: | stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsAbstract
Namespace Prefix: | stro_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone method revenue recognition. + References No definition available. + Details
Name: | stro_MilestoneMethodRevenueRecognitionTableTextBlock
Namespace Prefix: | stro_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765 + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration